GCP
DYN icon

GSA Capital Partners’s Dyne Therapeutics DYN Stock Holding History

GSA Capital Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,422
Closed -$615K – 1828
2025
Q4 		$615K Sell
31,422
-3,768
-11% -$71.4K 0.05% 669
2025
Q3 		$445K Buy
35,190
+21,259
+153% +$242K 0.04% 931
2025
Q2 		$133K Sell
13,931
-84,666
-86% -$932K 0.01% 1586
2025
Q1 		$1.03M Buy
+98,597
New +$1.41M 0.09% 324
2022
Q3 		– Sell
-15,996
Closed -$110K – 1606
2022
Q2 		$110K Sell
15,996
-11,947
-43% -$82.3K 0.02% 1205
2022
Q1 		$269K Buy
27,943
+4,750
+20% +$40.4K 0.04% 975
2021
Q4 		$276K Buy
23,193
+4,357
+23% +$61.2K 0.03% 996
2021
Q3 		$306K Buy
+18,836
New +$334K 0.03% 1002

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

GSA Capital Partners's DYN Position: Q1 2026 in Review

GSA Capital Partners sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 31,422 shares — an estimated $615K sold.

GSA Capital Partners first reported a position in DYN in Q3 2021 and held it in 8 quarters. The position peaked at $1.03M in Q1 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • GSA Capital Partners reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 31,422 Dyne Therapeutics shares in Q1 2026, an estimated $615K.
  • GSA Capital Partners first reported a position in Dyne Therapeutics in Q3 2021 and held it in 8 quarters.
  • GSA Capital Partners's Dyne Therapeutics position peaked at $1.03M in Q1 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.